SlideShare a Scribd company logo
1 of 27
Lecture 2
Learning objectives – 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Learning objectives  –  2 ,[object Object],[object Object],[object Object],[object Object],[object Object]
Learning objectives  –  3 ,[object Object],[object Object]
The common component of COPD is airflow obstruction Chronic bronchitis Emphysema Airflow obstruction Asthma
Summary of risk factors for the development of COPD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical features of advanced COPD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnostic measures recommended by major Thoracic Societies  ,[object Object],[object Object],[object Object],[object Object],[object Object],ATS. Am J Respir Crit Care Med 1995 ERS. Eur Respir J 1995  BTS. Thorax 1997 Pauwels RA, et al. Am J Respir Crit Care Med 2001
GOLD guidelines outline key points in COPD diagnosis Chronic cough Present intermittently or every day Often present throughout the day; seldom only nocturnal Chronic sputum production Any pattern of chronic sputum production may indicate COPD Dyspnoea that is: Progressive (worsens over time) Persistent (present every day) Described by the patient as an ‘increased effort to breathe’, or ‘gasping’ Worse during exercise Worse during respiratory infections History of exposure to risk factors, especially: Tobacco smoke Occupational dusts and chemicals Smoke from home cooking and heating fuels Pauwels RA, et al. Am J Respir Crit Care Med 2001
GOLD guidelines: Classification of severity of COPD Stage Characteristics 0: At risk - Normal spirometry - Chronic symptoms (cough, sputum production) I: Mild COPD - FEV 1 /FVC <70% - FEV 1    80% predicted - With or without chronic symptoms (cough, sputum    production) II: Moderate COPD - FEV 1 /FVC <70% - 30%   FEV 1  <80% predicted    (IIA: 50%   FEV 1  <80% predicted, IIB: 30%   FEV 1     <50% predicted) - With or without chronic symptoms    (cough, sputum production, dyspnoea) III: Severe COPD - FEV 1 /FVC <70% - FEV 1  <30% predicted or FEV 1  <50% predicted plus    respiratory failure or clinical signs of right heart    failure
What Is Asthma? ,[object Object],[object Object],[object Object]
Epidemiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Increase in Asthma Prevalence with Time 1982 1988 1992 1968 1982 1979 1984 1989 1975 1973 1971-74 1976-80 Source: Global Initiative for Asthma  NHLBI/WHO Workshop Report 1996   *Diagnosed asthma: asthma diagnosed at any time.  Asthma and/or wheeze.
Market Size  CAGR:  € + 14.7%  USD + 6.2%  SU - 0.2% annual growth rate % + 9.3 + 8.5   + 17.6  + 24.3 Asthma Worldwide: Value 1996 - 2000
Clinical Signs and Symptoms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pathophysiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ethnic Differences ,[object Object],[object Object],[object Object]
Diagnosis and Classification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Standard of Care ,[object Object],[object Object],[object Object]
GINA Stepwise Treatment Guidelines for Adults Cromolyn Theophylline Inhaled CS low/high dose Short-act   2 Long-act   2 Mild Intermittent Mild Persistent Moderate Persistent Severe Persistent GINA: Global Initiative for Asthma, CS: Corticosteroids, LTA: Leukotriene antagonist LTA Reliever Controller Oral CS
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Death Rates Are Increasing, Especially in North America
[object Object],[object Object],[object Object],[object Object],[object Object],Guidelines vs. Reality
Chest X-rays do not have a pivotal role in diagnosis of COPD   Hyperinflated lungs severe COPD Normal X-ray mild COPD
Measurements of lung function ,[object Object],[object Object],[object Object],[object Object],[object Object],*Also known as maximum expiratory flow (MEF)
Subdivisions of the total capacity of the lungs Total lung capacity Full inspiration Full expiration Tidal volume Residual volume Maximum forced inspiration Maximum forced expiration FVC
Lung function tests are pivotal for assessment of COPD severity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Asthma and nursing managements
Asthma and nursing managementsAsthma and nursing managements
Asthma and nursing managementsMEEQAT HOSPITAL
 
Asthma vs COPD - A quick summary of the differences between them
Asthma vs COPD - A quick summary of the differences between themAsthma vs COPD - A quick summary of the differences between them
Asthma vs COPD - A quick summary of the differences between themLGM Pharma
 
Asthma Presentation
Asthma PresentationAsthma Presentation
Asthma Presentationkerri035
 
Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008DJ CrissCross
 
Bp asthma canvas 2015
Bp asthma canvas 2015Bp asthma canvas 2015
Bp asthma canvas 2015Chelsea Elise
 
Asthma prevention Community medicine
Asthma prevention Community medicineAsthma prevention Community medicine
Asthma prevention Community medicineDr UAK
 
Asthma 2010
Asthma 2010Asthma 2010
Asthma 2010NorthTec
 

What's hot (20)

Asthma
Asthma Asthma
Asthma
 
Asthma
Asthma  Asthma
Asthma
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 
Asthma Project
Asthma ProjectAsthma Project
Asthma Project
 
Asthma and nursing managements
Asthma and nursing managementsAsthma and nursing managements
Asthma and nursing managements
 
Asthma
AsthmaAsthma
Asthma
 
Asthma vs COPD - A quick summary of the differences between them
Asthma vs COPD - A quick summary of the differences between themAsthma vs COPD - A quick summary of the differences between them
Asthma vs COPD - A quick summary of the differences between them
 
Asthma
AsthmaAsthma
Asthma
 
Asthma Presentation
Asthma PresentationAsthma Presentation
Asthma Presentation
 
ASTHAMA
ASTHAMAASTHAMA
ASTHAMA
 
Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008Global Initiative For Asthma Guidelines 2008
Global Initiative For Asthma Guidelines 2008
 
Bronchial asthma in children
Bronchial asthma in childrenBronchial asthma in children
Bronchial asthma in children
 
Asthma
AsthmaAsthma
Asthma
 
Bp asthma canvas 2015
Bp asthma canvas 2015Bp asthma canvas 2015
Bp asthma canvas 2015
 
Asthma prevention Community medicine
Asthma prevention Community medicineAsthma prevention Community medicine
Asthma prevention Community medicine
 
Asthma 2010
Asthma 2010Asthma 2010
Asthma 2010
 
Asthma
AsthmaAsthma
Asthma
 
Bronchial asthama
Bronchial asthamaBronchial asthama
Bronchial asthama
 
Asthma
AsthmaAsthma
Asthma
 
Asthma ppt
Asthma pptAsthma ppt
Asthma ppt
 

Similar to Asthma

8.Asthma
8.Asthma8.Asthma
8.Asthmaghalan
 
Pharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalPharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalAhmanurSule5
 
Asthma lecture 100829
Asthma lecture 100829Asthma lecture 100829
Asthma lecture 100829Neil Kao
 
Bronchial asthma and it's management
Bronchial asthma and it's managementBronchial asthma and it's management
Bronchial asthma and it's managementRakhiYadav53
 
ASTHMA and it's Physiotherapy Treatment.pptx
ASTHMA  and it's Physiotherapy Treatment.pptxASTHMA  and it's Physiotherapy Treatment.pptx
ASTHMA and it's Physiotherapy Treatment.pptxShilpasree Saha
 
Bronchial asthma in children
Bronchial asthma in children Bronchial asthma in children
Bronchial asthma in children Azad Haleem
 
Childhood asthma.pptx
Childhood asthma.pptxChildhood asthma.pptx
Childhood asthma.pptxDrHananTork
 
Bronchial asthma by dr.bakul
Bronchial asthma by dr.bakulBronchial asthma by dr.bakul
Bronchial asthma by dr.bakulBakul Arora
 
Childhood asthma diagnosis and management
Childhood asthma diagnosis and managementChildhood asthma diagnosis and management
Childhood asthma diagnosis and managementVirendra Hindustani
 
pharmacology of asthma
pharmacology of asthmapharmacology of asthma
pharmacology of asthmasimeon joseph
 

Similar to Asthma (20)

8
88
8
 
8.Asthma
8.Asthma8.Asthma
8.Asthma
 
9 asthma
9 asthma9 asthma
9 asthma
 
Pharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospitalPharmacotherapy of Asthmatic patient in hospital
Pharmacotherapy of Asthmatic patient in hospital
 
Disorder of organ system Pdf
Disorder of organ system PdfDisorder of organ system Pdf
Disorder of organ system Pdf
 
Asthma lecture 100829
Asthma lecture 100829Asthma lecture 100829
Asthma lecture 100829
 
Bronchial asthma and it's management
Bronchial asthma and it's managementBronchial asthma and it's management
Bronchial asthma and it's management
 
Asthma Posted 1018 06
Asthma Posted 1018 06Asthma Posted 1018 06
Asthma Posted 1018 06
 
INTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.pptINTEGRATED THERAPEUTICS I.ppt
INTEGRATED THERAPEUTICS I.ppt
 
COPD
COPDCOPD
COPD
 
ASTHMA and it's Physiotherapy Treatment.pptx
ASTHMA  and it's Physiotherapy Treatment.pptxASTHMA  and it's Physiotherapy Treatment.pptx
ASTHMA and it's Physiotherapy Treatment.pptx
 
Child asthma
Child asthmaChild asthma
Child asthma
 
Copd 2006
Copd 2006Copd 2006
Copd 2006
 
Asthma
AsthmaAsthma
Asthma
 
Bronchial asthma in children
Bronchial asthma in children Bronchial asthma in children
Bronchial asthma in children
 
Childhood asthma.pptx
Childhood asthma.pptxChildhood asthma.pptx
Childhood asthma.pptx
 
Bronchial asthma by dr.bakul
Bronchial asthma by dr.bakulBronchial asthma by dr.bakul
Bronchial asthma by dr.bakul
 
Childhood asthma diagnosis and management
Childhood asthma diagnosis and managementChildhood asthma diagnosis and management
Childhood asthma diagnosis and management
 
pharmacology of asthma
pharmacology of asthmapharmacology of asthma
pharmacology of asthma
 
Mahu copd
Mahu copdMahu copd
Mahu copd
 

More from Karl Daniel, M.D. (20)

menstrual cycle
menstrual cyclemenstrual cycle
menstrual cycle
 
vulvo vaginal infection
vulvo vaginal infectionvulvo vaginal infection
vulvo vaginal infection
 
vesicular molle 2
vesicular molle 2vesicular molle 2
vesicular molle 2
 
vesicular molle 1
vesicular molle 1vesicular molle 1
vesicular molle 1
 
Sexually Transmitted Infections
Sexually Transmitted InfectionsSexually Transmitted Infections
Sexually Transmitted Infections
 
Screening for Female Genital Tract Malignancy
Screening for Female Genital Tract MalignancyScreening for Female Genital Tract Malignancy
Screening for Female Genital Tract Malignancy
 
vaginal prolapse
vaginal prolapsevaginal prolapse
vaginal prolapse
 
prevention Cervical cancer
prevention Cervical cancerprevention Cervical cancer
prevention Cervical cancer
 
ovarian tumor
ovarian tumorovarian tumor
ovarian tumor
 
Contemporary Use of the Pessary
Contemporary Use of the PessaryContemporary Use of the Pessary
Contemporary Use of the Pessary
 
management of cancer of cervix
management of cancer of cervixmanagement of cancer of cervix
management of cancer of cervix
 
leiomyomas
leiomyomasleiomyomas
leiomyomas
 
fibroids
fibroidsfibroids
fibroids
 
endometriosis
endometriosisendometriosis
endometriosis
 
DnC
DnCDnC
DnC
 
carcinoma vulva
carcinoma vulvacarcinoma vulva
carcinoma vulva
 
amenorrhea
amenorrheaamenorrhea
amenorrhea
 
adenomyosis
adenomyosisadenomyosis
adenomyosis
 
Evidence Based Diagnosis
Evidence Based DiagnosisEvidence Based Diagnosis
Evidence Based Diagnosis
 
HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2HORMONE REPLACEMENT THERAPY 2
HORMONE REPLACEMENT THERAPY 2
 

Asthma

  • 2.
  • 3.
  • 4.
  • 5. The common component of COPD is airflow obstruction Chronic bronchitis Emphysema Airflow obstruction Asthma
  • 6.
  • 7.
  • 8.
  • 9. GOLD guidelines outline key points in COPD diagnosis Chronic cough Present intermittently or every day Often present throughout the day; seldom only nocturnal Chronic sputum production Any pattern of chronic sputum production may indicate COPD Dyspnoea that is: Progressive (worsens over time) Persistent (present every day) Described by the patient as an ‘increased effort to breathe’, or ‘gasping’ Worse during exercise Worse during respiratory infections History of exposure to risk factors, especially: Tobacco smoke Occupational dusts and chemicals Smoke from home cooking and heating fuels Pauwels RA, et al. Am J Respir Crit Care Med 2001
  • 10. GOLD guidelines: Classification of severity of COPD Stage Characteristics 0: At risk - Normal spirometry - Chronic symptoms (cough, sputum production) I: Mild COPD - FEV 1 /FVC <70% - FEV 1  80% predicted - With or without chronic symptoms (cough, sputum production) II: Moderate COPD - FEV 1 /FVC <70% - 30%  FEV 1 <80% predicted (IIA: 50%  FEV 1 <80% predicted, IIB: 30%  FEV 1 <50% predicted) - With or without chronic symptoms (cough, sputum production, dyspnoea) III: Severe COPD - FEV 1 /FVC <70% - FEV 1 <30% predicted or FEV 1 <50% predicted plus respiratory failure or clinical signs of right heart failure
  • 11.
  • 12.
  • 13. Increase in Asthma Prevalence with Time 1982 1988 1992 1968 1982 1979 1984 1989 1975 1973 1971-74 1976-80 Source: Global Initiative for Asthma NHLBI/WHO Workshop Report 1996 *Diagnosed asthma: asthma diagnosed at any time. Asthma and/or wheeze.
  • 14. Market Size CAGR: € + 14.7% USD + 6.2% SU - 0.2% annual growth rate % + 9.3 + 8.5 + 17.6 + 24.3 Asthma Worldwide: Value 1996 - 2000
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20. GINA Stepwise Treatment Guidelines for Adults Cromolyn Theophylline Inhaled CS low/high dose Short-act  2 Long-act  2 Mild Intermittent Mild Persistent Moderate Persistent Severe Persistent GINA: Global Initiative for Asthma, CS: Corticosteroids, LTA: Leukotriene antagonist LTA Reliever Controller Oral CS
  • 21.
  • 22. Death Rates Are Increasing, Especially in North America
  • 23.
  • 24. Chest X-rays do not have a pivotal role in diagnosis of COPD Hyperinflated lungs severe COPD Normal X-ray mild COPD
  • 25.
  • 26. Subdivisions of the total capacity of the lungs Total lung capacity Full inspiration Full expiration Tidal volume Residual volume Maximum forced inspiration Maximum forced expiration FVC
  • 27.

Editor's Notes

  1. COPD is often a mixture of conditions that have airflow obstruction as the common element. It is not unusual for a patient to present with three diagnoses – emphysema, chronic bronchitis and asthma, all of which have an element of poorly reversible airflow obstruction: such an individual would be classed as having COPD. Conversely, a patient may have simple emphysema or simple bronchitis with no airflow obstruction, and these individuals would not be classed as having COPD. Most cases of asthma have completely reversible airflow obstruction and on this basis can be differentially diagnosed from COPD. 1.2.5
  2. There are several other risk factors that play a role in COPD development but they are all minor compared with cigarette smoking. Occupational job exposure to hazardous airborne substances can increase the risk of COPD, especially in individuals who already smoke. Air pollution may cause respiratory symptoms but is unlikely to cause lung function deficiency. Hyperresponsive airways may play a role in the development of COPD and are not necessarily the result of allergy or atopy. The role of viral infections of the respiratory tract in the development of COPD are not clearly established. However, once COPD is established any respiratory infection will accelerate lung function decline. Less than 1% of COPD is thought to be due to AAT deficiency. 1.4.6
  3. In more advanced disease, the patient may show other characteristic signs of the illness. Cyanosis (bluish discolouration of skin and mucous membranes) may be present at rest or during mild exercise. An enlarged liver and distension of the veins in the neck are suggestive of cor pulmonale or heart failure. Anorexia and weight loss are not unusual and there may be evidence of an abnormal decrease in the amount of oxygen in the blood – hypoxaemia, and/or an abnormal increase in the amount of carbon dioxide in the blood – hypercapnia. Patients with end-stage disease typically adopt postures that relieve dyspnoea such as leaning forward while standing or sitting with their arms positioned forward on their knees. Exhalation often occurs through pursed lips which prevents collapse of the airways and provides some alleviation of discomfort. 2.1.2
  4. The main diagnostic measures of COPD are agreed by all guideline documents and include: history taking, symptomatic assessment, physical examination and spirometric measurements of lung function. 3.0.3
  5. The GOLD guidelines recommend that spirometry should be performed if any of the key indicators (chronic cough, sputum production, dyspnoea, patient history of exposure to risk factors) are present. These indicators are not diagnostic on their own but the presence of several of them increases the probability of a diagnosis of COPD. Spirometry is considered to be essential for establishing a diagnosis of COPD. The GOLD guidelines recommend that the most sensitive test is the FEV 1 /FVC ratio. A post-bronchodilator FEV 1 of  80% of the predicted value in combination with an FEV 1 /FVC of &lt;70% is thought to confirm the diagnosis of COPD. 3.0.6
  6. The GOLD guidelines classify disease severity into 4 stages: ‘At risk’ (0), ‘Mild COPD’ (I), ‘Moderate COPD’ (II) and ‘Severe COPD’ (III). The staging of COPD is based on airflow limitation as measured by spirometry, which is essential for diagnosis and provides a useful description of the severity of pathological changes in COPD. 3.0.7
  7. Deaths in the developed world ~ 45,000 [death rate ~ 5 per 100,000 patients]
  8. In mild COPD the chest X-ray may be normal. As the disease advances, hyperinflation of the chest is evident as larger lung volume, a low flat diaphragm, a thin heart shadow, a marginally increased heart size and an enlarged retrosternal air space on the lateral view. 2.1.3
  9. Two spirometric measurements are the most frequently used: FEV 1 and FVC, although IVC or IC (inspiratory capacity) is thought to be increasingly important. PEF can be measured using both a spirometer and peak flow meter. Measurement of FEV 1 , PEF and FVC alone is not enough to diagnose early-stage COPD. 2.2.1
  10. The spirometer can measure several different lung capacities that make up the total lung capacity. Usually the patient is asked to undergo a ‘forced’ measurement against time – FEV 1 is the most typically used and this measures the maximum forced expiration in one second. The tidal volume shows the volume of air in the lungs during ‘tidal breathing’ – the usual shallow breathing during rest. 2.2.2
  11. FEV 1 is generally the most useful test to assess severity and progression of COPD, although the ratio between FEV 1 and FVC is the most sensitive measure of early airflow obstruction as it is always below the usual adult value of approximately 80%. FEV 1 reduces as the disease progresses. FEF can also be used and reflects small airway function. It is markedly reduced in patients with COPD but has greater variability than FEV 1 and so is not valuable for routine monitoring. PEF can give a crude estimate of lung function. It is not useful for diagnosing COPD since PEF can be relatively well preserved in the early stages of disease. IVC (IC) is becoming an important lung function measurement in the assessment of COPD because patients tend to have more problems during inspiration than during expiration. 2.2.3